Due to its ability to irreversibly inactivate platelet cyclooxygenase, low-dose aspirin (ASA) is the most widely used antithrombotic agent. Although, studies in specific types of patients with cardiovascular disease (CVD) have shown an incomplete inhibition of platelet's cyclooxygenase, which may increase the variability in drug response. Some aspects of ASA pharmacokinetics (PK) still need further investigation. In this study, we aimed to characterise the contribution of esterase enzymes to ASA hydrolysis in the peripheral blood and to assess their activity in 36 healthy subjects (Ctrl) and 77 CVD patients.
Porro B, Di Minno A, Rocca B, Fiorelli S, Eligini S, Turnu L, Barbieri S, Parolari A, Tremoli E, Cavalca V. Characterization of aspirin esterase activity in health and disease: in vitro and ex vivo studies. Biochem Pharmacol 2019 Feb 13;163:119-127